Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Filings indexed 1,415 across all filing types
Latest filing 2026-05-22 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2026-05-22 English
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release dated May 22, 2026 announcing the voting results of Innate Pharma’s 2026 Annual General Meeting. It provides the resolutions, the number of votes cast, quorum percentage, and where related documents will be available. This clearly matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA) as it reports official shareholder vote outcomes at an AGM.
2026-05-22 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the detailed voting results of Innate Pharma’s mixed general meeting held on May 21, 2026. It provides the number of votes, quorum details, and confirms resolutions passed, fitting the definition of ‘Declaration of Voting Results & Voting Rights Announcements’. There is no substantive financial report or other primary content, and it is not a simple publication notice but explicitly discloses shareholder vote outcomes. Therefore, it should be classified as DVA.
2026-05-22 French
6-K
Foreign Filer Report
2026-05-19 English
Informations privilégiées / Autres communiqués
Regulatory Filings
2026-05-19 French
Inside Information / Other news releases
Regulatory Filings
2026-05-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.